Outputs (2)

Cost-Effectiveness of Initiating Pharmacological Treatment in Stage One Hypertension Based on 10-Year Cardiovascular Disease Risk: A Markov Modeling Study (2020)
Journal Article
Constanti, M., Floyd, C. N., Glover, M., Boffa, R., Wierzbicki, A. S., & Mcmanus, R. J. (2021). Cost-Effectiveness of Initiating Pharmacological Treatment in Stage One Hypertension Based on 10-Year Cardiovascular Disease Risk: A Markov Modeling Study. Hypertension, 77(2), 682-691. https://doi.org/10.1161/HYPERTENSIONAHA.120.14913

Antihypertensive drug treatment is cost-effective for adults at high risk of developing cardiovascular disease (CVD). However, the cost-effectiveness in people with stage 1 hypertension (140–159 mm Hg systolic blood pressure) at lower CVD risk remain... Read More about Cost-Effectiveness of Initiating Pharmacological Treatment in Stage One Hypertension Based on 10-Year Cardiovascular Disease Risk: A Markov Modeling Study.

Options for the diagnosis of high blood pressure in primary care: a systematic review and economic model (2020)
Journal Article
Constanti, M., Boffa, R., Floyd, C. N., Wierzbicki, A. S., McManus, R., & Glover, M. (2021). Options for the diagnosis of high blood pressure in primary care: a systematic review and economic model. Journal of Human Hypertension, 35, 455–461. https://doi.org/10.1038/s41371-020-0357-x

The 2011 NICE hypertension guideline (CG127) undertook a systematic review of the diagnostic accuracy of different blood pressure (BP) assessment methods to confirm the diagnosis of hypertension. The guideline also undertook a cost–utility analysis e... Read More about Options for the diagnosis of high blood pressure in primary care: a systematic review and economic model.